← Product Code [DSB](/submissions/CV/subpart-c%E2%80%94cardiovascular-monitoring-devices/DSB) · K131765 # ECOM ENDOTRACHEAL CARDIAC OUTPUT MONITOR SYSTEM (K131765) _Conmed Corporation · DSB · Dec 20, 2013 · Cardiovascular · SESE_ **Canonical URL:** https://fda.innolitics.com/submissions/CV/subpart-c%E2%80%94cardiovascular-monitoring-devices/DSB/K131765 ## Device Facts - **Applicant:** Conmed Corporation - **Product Code:** [DSB](/submissions/CV/subpart-c%E2%80%94cardiovascular-monitoring-devices/DSB.md) - **Decision Date:** Dec 20, 2013 - **Decision:** SESE - **Submission Type:** Traditional - **Regulation:** 21 CFR 870.2770 - **Device Class:** Class 2 - **Review Panel:** Cardiovascular ## Indications for Use The ECOM Endotracheal Cardiac Output Monitor System is intended for the monitoring of cardiac output by impedance cardiography while providing airway management by oral intubation with an ECOM Endotracheal Tube. The ECOM System is indicated for use in patients who are expected to be intubated for 24 hours or less and in whom an arterial pressure line is used. The ECOM System displays the R-Wave Detection and the Impedance Waveforms as well as the patient's Cardiac Output (CO), Stroke Volume (SV), Heart Rate (HR), Systolic and Diastolic Pressure. ## Device Story ECOM Endotracheal Cardiac Output Monitor System provides hemodynamic monitoring during airway management. System inputs include high-frequency, low-amplitude electrical current signals from electrodes on an endotracheal tube and arterial pressure signals. Device processes these inputs to calculate and display cardiac output (CO), cardiac index (CI), stroke volume (SV), stroke volume variation (SVV), heart rate (HR), systemic vascular resistance (SVR/SVRI), and blood pressures. Used in clinical settings by healthcare providers to monitor intubated patients. Output allows clinicians to assess hemodynamic status and guide clinical decision-making for patient management. Benefits include integrated airway management and real-time cardiac monitoring. ## Clinical Evidence Bench testing only. Design verification testing confirmed compliance with IEC 60601-1, 60601-1-1, 60601-1-2, and 60601-1-4 standards. Biocompatibility of patient-contacting materials verified per ISO 10993-1:2009. ## Technological Characteristics System includes monitor, endotracheal tube, and accessories. Employs impedance plethysmography via high-frequency, low-amplitude electrical current. Patient-contacting materials comply with ISO 10993-1:2009. Electrical safety compliance per IEC 60601-1, 60601-1-1, 60601-1-2, and 60601-1-4. ## Regulatory Identification An impedance plethysmograph is a device used to estimate peripheral blood flow by measuring electrical impedance changes in a region of the body such as the arms and legs. ## Special Controls *Classification.* Class II (special controls). The device, when it is a body composition analyzer which is not intended to diagnose or treat any medical condition, is exempt from the premarket notification procedures in subpart E of part 807 of this chapter subject to the limitations in § 870.9. ## Predicate Devices - ECOM CV4 Endotracheal Cardiac Output Monitor ([K032491](/device/K032491.md)) ## Submission Summary (Full Text) > This content was OCRed from public FDA records by [Innolitics](https://innolitics.com). If you use, quote, summarize, crawl, or train on this content, cite Innolitics at https://innolitics.com. > > Innolitics is a medical-device software consultancy. We help companies design, build, and clear FDA-regulated software and AI/ML devices, including [a 510(k)](https://innolitics.com/services/510ks/), [a De Novo](https://innolitics.com/services/regulatory/), [a SaMD](https://innolitics.com/services/end-to-end-samd/), [an AI/ML medical device](https://innolitics.com/services/medical-imaging-ai-development/), or [an FDA regulatory strategy](https://innolitics.com/services/regulatory/). {0}------------------------------------------------ # 510(k) Summary of Safety and Effectiveness ECOM™ Endotracheal Cardiac Output Monitoring System In accordance with the requirements of the Safe Medical Device Act of 1990 and 21CFR 807.92, ConMed Corporation is hereby submitting the 510(k) Summary of Safety and Effectiveness for 510(k) number ______________________________________________________________________________________________________________________________________________ #### A. Submitter ConMed Corporation 525 French Road Utica, NY 13502 Establishment Registration: 1320894 # B. Company Contact Lisa Anderson Manager, Regulatory Affairs T: (315) 624-3371 F: (315) 624-3225 #### C. Device Name Proprietary Name: Common Name: Classification Name: Regulation Number: Product Code: Regulatory Class: Panel: ECOM™ Endotracheal Cardiac Output Monitor System Plethysmograph, impedance Impedance plethysmograph 870.2770 DSB = Cardiovascular # D. Predicate Device | Device Name: | ECOM CV4 Endotracheal Cardiac Output Monitor | |---------------|----------------------------------------------------------------------| | Company Name: | ConMed Corporation via acquisition of Imagyn Medical
Technologies | | 510(k): | K032491 | # E. Device Description The ECOM Endotracheal Cardiac Output Monitor System consists of a monitor, an endotracheal tube and various accessories. The system applies a high frequency, low amplitude electrical current to a series of electrodes applied to the endotracheal tube. The resulting signals, when used in conjunction with an arterial pressure signal, allow for the calculation and display of Cardiac Output (CO). Cardiac Input (CI). Stroke Volume (SV), Stroke Volume Variation (SVV), Heart Rate (HR), Systemic Vascular 6-1 {1}------------------------------------------------ - Resistance (SVR), Systemic Vascular Resistance Index (SVRI), and systolic, diastolic and mean blood pressures. #### F. Intended Use / Indications for Use The ECOM Endotracheal Cardiac Output Monitor System is intended for the monitoring of cardiac output by impedance cardiography while providing airway management by oral intubation with an ECOM Endotracheal Tube. The ECOM System is indicated for use in patients who are expected to be intubated for 24 hours or less and in whom an arterial pressure line is used. The ECOM System displays the R-Wave Detection and the Impedance Waveforms as well as the patient's Cardiac Output (CO), Stroke Volume (SV), Heart Rate (HR), Systolic and Diastolic Pressure. #### G. Non-clinical Performance Testing Non-clinical bench testing demonstrated the ConMed ECOM Endotracheal Cardiac Output Monitor System is substantially equivalent to the predicate with regard to intended use, materials, technology, and performance. Design verification testing, including software validation, demonstrates the system complies with the applicable sections of IEC 60601-1:1988/A1:1991/A2:1995, IEC 60601-1-1:2000, IEC 60601-1-2:2001/A1:2004 and IEC 60601-1-4:2000. Material analysis demonstrates the patient contacting materials comply with the requirements of ISO 10993-1:2009. #### H. Substantial Equivalence The differences between the predicate and the modified design do not raise any new risks of safety or efficacy. Supporting information per this premarket submission confirms that the ConMed ECOM Endotracheal Cardiac Output Monitor System is safe and effective for the intended use and is substantially equivalent to the predicate device. {2}------------------------------------------------ # DEPARTMENT OF HEALTH & HUMAN SERVICES Public Health Service Food and Drug Administration 10903 New Hampshire Avenue Document Control Center - WO66-G609 Silver Spring, MD 20993-0002 December 20, 2013 ConMed Corporation Ms. Lisa Anderson Manager, Regulatory Affairs 525 French Road Utica, NY 13502 Re: K131765 : Trade/Device Name: ECOM® Endotracheal Cardiac Output Monitor System Regulation Number: 21 CFR 870.2770 Regulation Name: Impedance Plethysmograph Regulatory Class: Class II (two) Product Code: DSB Dated: November 19, 2013 Received: November 20, 2013 Dear Ms. Anderson: We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration. Please note: CDRH does not evaluate information related to contract liability warranties. We remind you; however, that device labeling must be truthful and not misleading. If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 898. In addition. FDA may publish further announcements concerning your device in the Federal Register. {3}------------------------------------------------ ## Page 2 - Ms. Lisa Anderson Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Part 801); medical device reporting (reporting of medical device-related adverse events} (21 CFR 803); good manufacturing practice requirements as set forth in the quality systems (OS) regulation (21 CFR Part 820); and if applicable, the electronic product radiation control provisions (Sections 531-542 of the Act); 21 CFR 1000-1050. If you desire specific advice for your device on our labeling regulation (21 CFR Part 801), please go to http://www.fda.gov/AboutFDA/CentersOffices/CDRHOffices/ucm115809.htm for the Center for Devices and Radiological Health's (CDRH's) Office of Compliance. Also, please note the regulation entitled. "Misbranding by reference to premarket notification" (21CFR Part 807.97). For questions regarding the reporting of adverse events under the MDR regulation (21 CFR Part 803), please go to http://www.fda.gov/MedicalDevices/Safety/ReportaProblem/default.htm for the CDRH's Office of Surveillance and Biometrics/Division of Postmarket Surveillance. You may obtain other general information on your responsibilities under the Act from the Division of Small Manufacturers, International and Consumer Assistance at its toll-free number (800) 638-2041 or (301) 796-7100 or at its Internet address http://www.fda.gov/MedicalDevices/ResourcesforYou/Industry/default.htm. Sincerely yours, # Owen P. Faris -S Bram D. Zuckerman for Director Division of Cardiovascular Devices Office of Device Evaluation Center for Devices and Radiological Health Enclosure {4}------------------------------------------------ # K131765 510(k) Number (if known): Device Name: ECOM® Endotracheal Cardiac Output Monitor System Indications for Use: The ECOM Endotracheal Cardiac Output Monitor System is intended for the monitoring of cardiac output by impedance cardiography while providing airway management by oral intubation with an ECOM Endotracheal Tube. The ECOM System is indicated for use in patients who are expected to be intubated for 24 hours or less and in whom an arterial pressure line is used. The ECOM System will display the R-Wave Detection and the Impedance Waveforms as well as the patient's Cardiac Output (CO), Stroke Volume (SV), Heart Rate (HR), Systolic and Diastolic Pressure. × Prescription Use (Part 21 CFR 801 Subpart D) AND/OR Over-The-Counter Use (21 CFR 801 Subpart C) (PLEASE DO NOT WRITE BELOW THIS LINE-CONTINUE ON ANOTHER PAGE OF NEEDED) . . . Concurrence of CDRH, Office of Device Evaluation (ODE) Digitally signed by Owen P. Faris -S Date: 2013.12.20 14:01:42 -05'00' Page 1 of 1 --- **Source:** [https://fda.innolitics.com/submissions/CV/subpart-c%E2%80%94cardiovascular-monitoring-devices/DSB/K131765](https://fda.innolitics.com/submissions/CV/subpart-c%E2%80%94cardiovascular-monitoring-devices/DSB/K131765) **Published by [Innolitics](https://innolitics.com)** — a medical-device software consultancy. We help companies design, build, and clear FDA-regulated software and AI/ML devices. If you're preparing [a 510(k)](https://innolitics.com/services/510ks/), [a De Novo](https://innolitics.com/services/regulatory/), [a SaMD](https://innolitics.com/services/end-to-end-samd/), [an AI/ML medical device](https://innolitics.com/services/medical-imaging-ai-development/), or [an FDA regulatory strategy](https://innolitics.com/services/regulatory/), [get in touch](https://innolitics.com/contact). **Cite:** Innolitics at https://innolitics.com